Contingent value rights have become one of the defining deal mechanics of pharmaceutical M&A. When an acquirer and seller cannot agree on the value of an unproven pipeline asset, a CVR bridges the gap by allowing sellers to participate in upside they believe exists while giving acquirers protection against paying for value that may never materialize. That alignment of incentives is real and powerful, but the legal architecture required to make a CVR function fairly is considerably more demanding than most parties appreciate when they first agree to the structure. From milestone definition to efforts obligations to tax treatment and post-closing litigation risk, CVRs require careful legal craftsmanship at every stage.
1. The Economic Rationale for CVRs in Pharmaceutical Transactions
Pharmaceutical acquisitions differ from most M&A transactions in one fundamental respect: a significant portion of the target's value often depends on regulatory events that have not yet occurred. A compound approaching Phase 3 data readout, a biologics license application pending FDA review, or a marketed product awaiting approval for a new indication all represent real value that is deeply uncertain. Sellers who have invested years developing an asset believe the probability of success is high. Acquirers, who have seen pipelines fail repeatedly, price in meaningful probability of failure. The result is a valuation gap that cash alone cannot easily close.
A CVR resolves this standoff by converting the disputed value into a contingent payment obligation. If the regulatory approval is received, the CVR pays. If the product achieves a defined sales threshold, the CVR pays. If neither event occurs within the milestone period, the CVR expires without payment. The acquirer pays a lower headline price at closing and bears reduced risk of overpayment. The seller receives a higher theoretical total consideration if the pipeline performs as expected. Both parties are economically aligned on milestone achievement, at least in theory.
The practical complications arise after closing. Once the acquisition is complete, the acquirer controls the pipeline. The seller and its stockholders, now CVR holders, have no management rights, no board representation, and no direct ability to influence development or commercial decisions. Their only recourse is contractual enforcement of the CVR agreement. This asymmetry means the quality of the CVR agreement itself determines whether the contingent value is ever realizable. Poorly drafted CVRs favor the acquirer almost by default, because the acquirer will be the party interpreting ambiguous terms and making the operational decisions that determine whether milestones are achieved.
This structural asymmetry is not a reason to avoid CVRs. It is a reason to negotiate and draft them with the rigor they deserve. Sellers' counsel should approach every CVR agreement with the assumption that a dispute will eventually arise and that the written terms will be the only governing document. Acquirers' counsel should approach the same document knowing that courts will apply contract interpretation principles that do not favor either party and that bad faith avoidance of milestones carries real litigation risk.
2. Regulatory Milestone CVR Design
A regulatory milestone CVR pays upon achievement of a specific approval or authorization from a regulatory authority. In the United States, this typically means FDA approval of a new drug application, biologics license application, or supplemental application for an additional indication. In the European Union, it means a marketing authorization from the European Medicines Agency or a national competent authority under the mutual recognition or decentralized procedure. In each case, the milestone must be defined with enough precision that its satisfaction is objective and verifiable, not subject to good-faith disagreement about what the regulatory action required.
The most important drafting decisions in a regulatory milestone CVR concern the definition of the qualifying approval. Does the approval need to cover the full patient population studied in the pivotal trial, or does a narrower label satisfy the milestone? If the FDA approves the drug with a Risk Evaluation and Mitigation Strategy that limits distribution, does that constitute full approval for CVR purposes? If the agency grants accelerated approval under 21 C.F.R. Part 601 based on a surrogate endpoint but requires a confirmatory trial, is the accelerated approval the triggering event, or does the CVR require traditional approval following the confirmatory study? Each of these questions has significant economic implications and each is a litigation waiting to happen if not resolved in the agreement.
Counsel should also address parallel regulatory pathways. Many pharmaceutical acquirers pursue FDA approval and EMA authorization simultaneously, but approval timelines differ between jurisdictions. If the CVR triggers on the first major market approval, the payment may occur on an EMA timeline rather than FDA. If it triggers only on FDA approval, European approval has no CVR effect. The agreement should specify which regulatory actions trigger payment, in which jurisdictions, and whether multiple approvals generate multiple payments or a single payment regardless of the number of regulatory events.
The milestone period requires equal attention. FDA approval timelines are inherently uncertain. A complete response letter, a request for additional clinical data, or a manufacturing inspection deficiency can delay approval by one to three years without any fault on the acquirer's part. The CVR agreement must set a milestone period long enough to accommodate plausible regulatory delays while short enough to avoid perpetual exposure. Standard pharmaceutical CVRs typically run five to ten years from closing, with the milestone period calibrated against the expected regulatory timeline plus a reasonable buffer. Automatic extension provisions triggered by regulatory delay events can reduce milestone period disputes without indefinitely extending acquirer exposure.
3. Sales Milestone CVR Design
Sales milestone CVRs pay when a product achieves defined commercial performance thresholds, measured by annual net sales, cumulative net sales, or both. These milestones are more controllable by the acquirer than regulatory milestones, because commercial performance depends heavily on marketing investment, pricing strategy, contracting decisions with payers, and sales force deployment, all of which the acquirer controls after closing. This controllability makes the commercially reasonable efforts obligation more practically significant in a sales milestone context than in a pure regulatory milestone context.
The definition of net sales is one of the most contested terms in any CVR with a sales component. Net sales typically means gross sales invoiced to customers, reduced by chargebacks, rebates, allowances, returns, and distribution fees. Each of these deductions is a negotiated term. The definition of chargebacks matters because government pricing programs, particularly Medicaid rebates under 42 U.S.C. Section 1396r-8 and the 340B drug pricing program, can generate deductions that significantly reduce reported net sales relative to gross revenue. Acquirers will argue these are legitimate deductions; CVR holders will argue that overly broad net sales definitions create incentives to maximize deductions at the expense of milestone achievement.
Annual net sales thresholds must be set against realistic market expectations, accounting for competitive entrants, patent expiration timelines, and payer coverage dynamics that may develop after closing. A sales threshold set against the most optimistic market forecast provides illusory value. A threshold calibrated against reasonable commercial projections, with step-up payments for exceeding each tier, more accurately reflects the value-sharing structure both parties intended. Tiered payment structures, where higher sales levels generate higher CVR payments, are increasingly common as they better capture the full commercial upside scenario sellers are trying to preserve.
Acquirers should also address the intersection of sales milestones and product lifecycle management decisions. If the acquirer decides to pursue a formulation change, a new indication, or a line extension for the CVR product, do sales of the new formulation or indication count toward the milestone? If the acquirer licenses the product to a regional partner in a geography where it lacks a sales force, do the licensee's net sales count? The CVR agreement should define the product scope and the scope of qualifying sales activities clearly, or these questions will generate disputes that neither party anticipated at signing.
4. Combined Regulatory and Sales Milestone Structures
Many pharmaceutical CVR agreements include both regulatory and sales milestones in the same instrument, creating a layered payment structure tied to both clinical and commercial success. A typical structure might pay a fixed amount on FDA approval, a second amount when annual net sales first exceed a lower threshold, and a third amount when annual net sales first exceed a higher threshold. This layering reflects the reality that regulatory approval and commercial success are related but distinct achievements, and that seller value arguments often rest on both dimensions.
The legal complexity of combined structures lies in the interaction between milestone types. If the regulatory milestone is not achieved, sales milestones may be moot because the product cannot be commercialized in the United States. Conversely, if the product receives regulatory approval but the acquirer prices it in a way that limits commercial uptake, the regulatory milestone pays but the sales milestones remain unachieved. CVR holders may argue that pricing decisions deliberately below market suppress sales milestone achievement in bad faith. Acquirers will argue that pricing decisions are ordinary course commercial judgments protected by the business judgment rule and not subject to second-guessing by CVR holders.
Combined structures also require careful attention to the temporal relationship between milestones. Should the sales milestone period begin on the date of regulatory approval, giving the acquirer a fixed commercial window, or should it begin on the closing date, creating pressure to achieve approval quickly in order to preserve commercial milestone time? Each choice creates different incentives and different litigation scenarios. Beginning the sales milestone period on the approval date is generally more equitable to CVR holders but may be resisted by acquirers who bear the approval risk.
Independent calculation agents can reduce disputes in combined structures by creating a neutral party responsible for determining whether milestones have been achieved and CVR payments calculated correctly. The calculation agent's role, standard of review, and dispute procedures should be defined in the CVR agreement, including whether the calculation agent's determination is binding absent manifest error, which party bears the cost of independent review, and what records the acquirer must provide to support milestone determinations.
5. Commercially Reasonable Efforts Obligations
The efforts standard is the single most legally significant term in any CVR agreement. Once the acquisition closes, CVR holders have no management rights and no ability to compel specific operational decisions. Their only protection against an acquirer that deprioritizes milestone achievement is the contractual efforts obligation and the implied covenant of good faith and fair dealing. The quality of drafting and the choice of efforts standard determine whether that protection is meaningful or largely theoretical.
Commercially reasonable efforts, the standard most commonly used in pharmaceutical CVR agreements, requires the obligated party to exert efforts consistent with what a reasonable company in the same business would exert to achieve the objective, taking into account the commercial and strategic context, the costs and benefits of available actions, and the party's own resources and priorities. This is an objective standard benchmarked against industry practice, not a purely subjective assessment of the acquirer's internal priorities. An acquirer that redirects an entire development team away from a CVR compound to a competing internal program without business justification other than preference cannot claim commercially reasonable efforts compliance simply because the decision seemed sensible internally.
The standard does permit acquirers to weigh the CVR obligation against other portfolio priorities, provided that weighting reflects genuine commercial judgment rather than a desire to avoid milestone payments. Courts applying commercially reasonable efforts will look at whether the acquirer maintained adequate resources for the CVR program, whether it responded appropriately to regulatory requests and requirements, whether it made commercialization decisions consistent with what it would have made absent the contingent payment obligation, and whether it documented its decisions in a way that reflects genuine business reasoning. The absence of contemporaneous documentation of business rationale is a significant red flag in CVR litigation.
Diligent efforts and commercially reasonable best efforts occupy intermediate positions between commercially reasonable efforts and best efforts. Diligent efforts typically signals a higher level of commitment than commercially reasonable efforts but does not eliminate cost-benefit weighing entirely. Commercially reasonable best efforts is a hybrid that courts have sometimes treated as equivalent to commercially reasonable efforts and sometimes treated as a heightened standard. The ambiguity in these formulations means that CVR parties should, where possible, supplement the general efforts standard with specific obligations: minimum development spending, required regulatory submission timelines, mandated commercial launch milestones, and required reporting to the CVR trustee.
6. Delaware Case Law: Williams Companies, Fortis Advisors, and the Efforts Standard
Delaware has produced a substantial body of case law interpreting efforts obligations in M&A earnout and CVR contexts. The Williams Companies line of cases established early that commercially reasonable efforts is a genuine contractual obligation, not merely a statement of intent. Courts applying Williams Companies have held that a party subject to a commercially reasonable efforts obligation cannot simply declare that other priorities are more important and abandon the obligated course of action. The obligation requires affirmative action, not merely the absence of active sabotage.
Fortis Advisors v. Johnson and Johnson, decided by the Delaware Court of Chancery, addressed commercially reasonable efforts in the context of a CVR tied to an acquisition of a pharmaceutical company. The court examined in detail whether the acquirer's post-closing commercial decisions satisfied the efforts standard it had assumed in the merger agreement. The court's analysis focused on the acquirer's resource allocation, its strategic prioritization decisions, and the extent to which its commercial choices deviated from what a reasonable company in the same position would have done absent the contingent payment obligation. The decision has become a reference point for Delaware courts evaluating CRE claims and has reinforced that post-closing efforts obligations in CVR agreements are judicially enforceable.
The practical lesson from Delaware CVR jurisprudence is that acquirers cannot treat the milestone period as an opportunity to run out the clock. Courts will evaluate the totality of post-closing conduct, and patterns of consistent deprioritization, even if individually justified, can amount to a breach of commercially reasonable efforts. Acquirers should maintain milestone achievement committees, document commercial rationale for resource allocation decisions, and preserve communications about pipeline strategy throughout the earnout period. The documentation burden is real but manageable, and it is far less costly than defending a well-pled breach of efforts obligation after the milestone period expires.
Delaware courts have also addressed the implied covenant of good faith and fair dealing in CVR contexts. The implied covenant prohibits conduct that, while not expressly forbidden by the agreement, would deprive the other party of the benefit of its bargain. In CVR disputes, CVR holders have invoked the implied covenant when acquirers took actions not specifically addressed in the agreement but clearly designed to prevent milestone achievement. Courts have granted implied covenant claims in these circumstances where the acquirer's conduct could not reasonably be justified as ordinary course business judgment.
7. Tax Treatment of CVRs: Open Transaction Doctrine and Installment Method
The tax treatment of CVRs received by selling stockholders in a pharmaceutical acquisition is one of the most technically complex areas of transaction tax law. The fundamental question is when and how selling stockholders must recognize income with respect to the contingent payment right. The answer depends on whether the CVR is treated as property with an ascertainable fair market value at the time of the transaction or whether it qualifies for deferral under the open transaction doctrine or the installment sale rules.
Under the open transaction doctrine, recognized in Burnet v. Logan and its progeny, a seller who receives consideration whose fair market value cannot be reasonably ascertained at the time of the sale is not required to include that consideration in the amount realized until the contingency is resolved and payment is actually received. The seller first recovers basis, and only after full basis recovery is any gain recognized. The IRS has consistently attempted to narrow this doctrine, arguing that most contingent payment rights have an ascertainable fair market value that can be determined using option pricing models or probability-weighted discounted cash flow analysis. Courts have generally deferred to the IRS's position, and open transaction treatment is now available only in genuinely exceptional circumstances where the contingency is highly uncertain and standard valuation methods genuinely cannot produce a reliable estimate.
The installment method under Section 453 and Treasury Regulation 15a.453-1 provides a more reliable path to deferred gain recognition for CVR holders. If the sale qualifies as an installment sale and the CVR payments are contingent installment obligations, the seller may spread gain recognition over the years in which payments are actually received, using a basis recovery computation prescribed by the regulations. However, installment treatment is not available for all transactions. Sales of publicly traded stock do not qualify, nor do sales to which the dealer rule or recapture provisions apply. The interaction between the installment method and corporate reorganization treatment, which is common in pharmaceutical acquisitions structured as tax-free mergers, requires careful analysis because installment obligations received in a reorganization may themselves be treated as boot and may disqualify the reorganization from tax-free treatment.
Sellers in pharmaceutical CVR transactions should obtain tax counsel advice on the interaction of these rules before signing, not after. The tax treatment of the CVR at closing affects the economics of the deal for every selling stockholder, and last-minute tax analysis can produce surprises that alter deal value significantly. Acquirers have corresponding tax interests in how the CVR is characterized, particularly if the CVR payments are deductible by the acquirer when paid, which depends on whether the CVR is treated as additional purchase price or as a compensation arrangement.
8. SEC Registration Considerations for Tradable CVRs
A CVR that is transferable and listed for trading constitutes a security within the meaning of Section 2(a)(1) of the Securities Act of 1933. Tradable CVRs issued in connection with a registered merger or exchange offer must be registered under the Securities Act unless an exemption applies. Because pharmaceutical acquisitions involving public target companies typically require a registration statement on Form S-4 or an exchange offer Schedule TO, the CVRs issued in those transactions are registered as part of the same transaction process and are reflected in the merger proxy or offer documents.
Once registered and issued, tradable CVRs are subject to Exchange Act reporting obligations if the acquirer is a public company and the CVRs meet the registration threshold. Section 12(g) reporting is triggered when a registered class of equity securities is held by more than 300 persons of record following a transaction that reduced the number of holders below the 2000-holder threshold, or more generally when the class has more than 2000 holders of record and the issuer has assets exceeding $10 million. CVR issuers that do not wish to incur ongoing Exchange Act reporting should structure the transaction to stay below these thresholds or seek a no-action position from the SEC staff, which has historically been available for non-tradable CVRs.
The antifraud provisions of Section 10(b) of the Exchange Act and Rule 10b-5 apply to tradable CVRs. An acquirer that makes material misstatements about milestone achievement prospects, progress toward regulatory approval, or commercial performance of a CVR product faces securities fraud exposure to the market of CVR holders. This exposure is distinct from the contract claims that non-tradable CVR holders can assert, and it carries different remedies, including class action damages under Section 10(b) and disgorgement under SEC enforcement actions. The securities law overlay on tradable CVR management obligations is a material consideration in the decision whether to structure a CVR as tradable or non-tradable.
Transfer agent appointment, DTC eligibility, and exchange listing requirements for tradable CVRs add administrative complexity that acquirers often underestimate. DTC eligibility requires the issuer to satisfy DTCC's operational and financial requirements, appoint a DTC-eligible transfer agent, and complete the DTC eligibility application process, which can take several months. Exchange listing for CVRs is available on some exchanges but not others, and listing standards may impose additional disclosure or governance requirements. Acquirers considering tradable CVR structures should engage securities counsel and their transfer agent well before closing to ensure the operational infrastructure is in place to support listing and trading on the intended timeline.
9. CVR Trustee Role and Appointment
A CVR trustee is appointed under the CVR agreement to serve as the representative and agent of CVR holders as a group. Because CVR holders are often dispersed among thousands of former stockholders of the acquired company, the trustee provides the practical mechanism for monitoring acquirer compliance, receiving acquirer reporting, and, when necessary, initiating legal action to enforce CVR holder rights. The trustee's role is entirely contractual, defined by the CVR agreement, without the overlay of statutory duties that applies to trustees under the Trust Indenture Act for registered debt securities.
The selection of a CVR trustee is a negotiated deal term. Corporate trust departments of major financial institutions, specialized litigation trustees, and law firms have all served as CVR trustees in pharmaceutical transactions. The trustee's institutional resources, independence from the acquirer, willingness to pursue litigation, and fee structure are all relevant selection criteria. A trustee that is a banking affiliate of the acquirer's deal bank creates at minimum an appearance of conflict of interest, even if the trust agreement contains adequate independence provisions. Sellers' counsel should push for a trustee with no existing relationship to the acquirer.
The CVR agreement defines the trustee's authority in detail. Key provisions include whether the trustee can initiate litigation on behalf of CVR holders without direction from a specified percentage of holders, what rights holders percentage is required to direct the trustee to take specific action, what indemnification the acquirer provides to the trustee for actions taken in good faith, and what fee the trustee receives for ongoing administration and for litigation management. Trustees that bear litigation risk without adequate indemnification will either refuse to act or demand fee structures that reduce the net recovery to CVR holders. The agreement should balance the trustee's need for protection with the holders' interest in having an active enforcement agent.
Rights holder group dynamics are an underappreciated aspect of CVR governance. Former stockholders of an acquired pharmaceutical company typically hold CVRs in proportion to their pre-merger stock holdings. Institutional holders may hold large CVR positions and have both the economic incentive and the resources to monitor compliance and fund litigation. Retail holders typically lack the resources to act individually. The trustee structure is designed to aggregate these dispersed interests, but in practice the institutional holders often drive enforcement decisions by exercising their contractual right to direct the trustee. The CVR agreement should contain clear provisions about the voting and direction rights of large holders, including anti-coercion provisions that protect small holders from pressure by large holders seeking to settle claims in ways that disproportionately benefit the large holders.
10. Key CVR Litigation Outcomes: Sanofi/Genzyme, Shire/NPS, and Aerpio
The Sanofi/Genzyme CVR arose from Sanofi's 2011 acquisition of Genzyme, in which each Genzyme stockholder received a tradable CVR tied to the commercial performance of alemtuzumab (later branded Lemtrada) in multiple sclerosis and certain manufacturing and filing milestones for other Genzyme products. The CVR was listed on NASDAQ, providing price discovery and liquidity, and was followed by investors and analysts tracking Lemtrada's clinical development and commercial launch. The transaction became a significant reference point for how tradable CVRs function in practice, including the market's skepticism about milestone achievement and the tension between acquirer commercial judgment and CVR holder expectations. Lemtrada ultimately received FDA approval and several CVR milestones were triggered, though not on the timeline the market had initially anticipated, illustrating the valuation and timing risk inherent in pharmaceutical CVRs.
The Shire/NPS litigation arose from Shire's acquisition of NPS Pharmaceuticals in 2015, which included a CVR tied to regulatory and commercial milestones for NPS's products. Disputes arose over the interpretation of milestone definitions, the sufficiency of Shire's commercial efforts, and the calculation methodology for net sales. The litigation illustrated several recurring CVR drafting vulnerabilities: net sales definitions with ambiguous deduction provisions, commercially reasonable efforts standards without specific operational benchmarks, and milestone periods that created timing disputes about when precisely a milestone had been achieved. The case reinforced the importance of drafting CVR agreements with operational specificity that leaves minimal room for interpretive dispute.
Aerpio Pharmaceuticals' CVR litigation, arising from its acquisition by Roche, addressed the acquirer's obligation to pursue clinical development of a CVR asset that Roche ultimately decided not to advance. CVR holders alleged that Roche's decision to discontinue the development program was a breach of its commercially reasonable efforts obligation. The case raised the fundamental tension that arises in all CVR structures: the acquirer has the authority to make development decisions but the CVR agreement constrains the exercise of that authority. Courts evaluating these claims must determine whether the acquirer's decision not to develop a program represents legitimate commercial judgment or a bad faith avoidance of milestone liability. The answer turns on the quality of the acquirer's internal decision-making process and the documentation supporting its developmental conclusions.
11. Set-Off Rights, Termination, and Expiration Mechanics
CVR agreements typically give acquirers the right to set off against CVR payments any amounts owed by CVR holders or the selling stockholder group under the merger agreement, including indemnification claims arising from representations and warranty breaches. Set-off rights create significant practical tension because CVR payments may be due years after closing, at which point indemnification disputes may still be pending. An acquirer that withholds a CVR payment pending resolution of an unrelated indemnification claim has, in effect, used the CVR as leverage in a separate dispute. CVR agreements should define the scope of set-off rights narrowly, require the acquirer to provide specific written notice of any intended set-off with detailed supporting information, and provide an expedited dispute resolution mechanism for challenging improper set-offs.
Termination provisions address the conditions under which the CVR agreement can be terminated before the expiration of the milestone period. Standard termination events include mutual written consent of the acquirer and a threshold percentage of CVR holders, entry of a court order invalidating the CVR agreement, or the acquirer's determination that all milestone payment obligations have been discharged. CVR agreements should not permit unilateral termination by the acquirer, as that would convert the CVR into a contractual right terminable at will, which would undermine the entire purpose of the instrument. Any termination provision requiring CVR holder consent should set a consent threshold high enough to prevent large institutional holders from railroading a settlement that does not adequately compensate retail holders.
Expiration mechanics define what happens when a milestone period ends without the milestone having been achieved. The standard result is that the CVR expires without value and the acquirer has no further payment obligation. However, acquirers should be careful about provisions that purport to extinguish CVR claims arising from pre-expiration breaches of efforts obligations. A CVR that expires at the end of the milestone period does not extinguish a claim for breach of commercially reasonable efforts that occurred during the period, because the breach gave rise to a cause of action at the time it occurred. Delaware courts have rejected attempts to use expiration provisions to bar pre-expiration breach claims, treating the expiration of the payment right as separate from the survival of accrued claims for damages.
The practical consequence is that acquirers face potential CVR litigation even after the milestone period expires if CVR holders can allege that efforts standard breaches during the period caused the milestone not to be achieved. Statutes of limitation, laches, and proof problems increase with time, but the theoretical liability window extends well beyond the expiration of the payment obligation. Acquirers should maintain records documenting their milestone efforts throughout the period and should not assume that expiration of the CVR forecloses all potential claims.
12. Dispute Resolution Mechanics
CVR agreements typically include dispute resolution provisions that specify how disagreements about milestone achievement, payment calculations, and efforts obligation compliance are to be resolved. The choice between litigation, arbitration, and expert determination has significant practical consequences for CVR holders and acquirers alike. Litigation in Delaware courts provides access to a sophisticated judiciary with deep M&A expertise but can be costly and slow. Arbitration offers confidentiality and potentially faster resolution but limits appellate review and may disadvantage CVR holders who cannot match the acquirer's resources in an extended arbitral proceeding.
Expert determination is particularly well-suited for disputes about factual matters within specific technical domains. If the CVR dispute concerns whether net sales were calculated correctly under the agreement's accounting definitions, a neutral accountant or financial expert can often resolve the dispute more efficiently than a court or arbitral panel. If the dispute concerns whether a regulatory milestone was satisfied, a regulatory expert familiar with FDA labeling standards may be better positioned than a generalist judge to evaluate the parties' competing interpretations. CVR agreements increasingly include tiered dispute resolution provisions: expert determination for defined categories of technical disputes, followed by arbitration or litigation for legal interpretation questions that the expert cannot resolve.
Specific performance and injunctive relief provisions deserve particular attention in CVR dispute resolution provisions. If an acquirer is about to take an action that would permanently impair milestone achievement, such as discontinuing a pivotal clinical trial or voluntarily withdrawing a regulatory application, CVR holders may need emergency injunctive relief to prevent the action before it becomes irreversible. The CVR agreement should expressly acknowledge that CVR holders may seek injunctive relief without bond, that irreparable harm will be presumed in defined circumstances, and that the dispute resolution provisions do not limit the availability of emergency equitable relief in courts of competent jurisdiction. Without these provisions, acquirers may argue that the dispute resolution clause is the exclusive remedy and that injunctive relief is unavailable even when the need is urgent.
The governing law and jurisdiction for CVR disputes is ordinarily Delaware, consistent with the governing law of the merger agreement and the incorporation state of most pharmaceutical companies involved in significant U.S. transactions. Delaware's Court of Chancery is well-suited for CVR disputes because it has equity jurisdiction to grant injunctive and specific performance remedies, its judges have extensive experience with complex M&A contracts, and its expedited procedures allow urgent matters to be heard on an accelerated schedule. Parties that choose to arbitrate should consider whether to seat the arbitration in Delaware and whether Delaware law should continue to govern even in an arbitral forum.
Frequently Asked Questions: CVR Structuring in Pharmaceutical M&A
Why does milestone definition precision matter so much in CVR agreements?
Imprecise milestone definitions are the most common source of CVR disputes. If a regulatory milestone says 'FDA approval' without specifying the indication, dosage form, or patient population, the acquirer may argue that approval of a narrowed label satisfies the milestone while the CVR holders argue it does not. Delaware courts apply ordinary contract interpretation principles, so every defined term becomes load-bearing. Acquirers and sellers should agree in detail on the precise regulatory action required, the labeling language that would constitute satisfaction, and whether partial approvals or accelerated approvals under 21 U.S.C. Section 601 qualify. The drafting investment at signing pays for itself many times over in avoided litigation.
What is the legal difference between 'commercially reasonable efforts' and 'best efforts' in a CVR context?
Delaware courts have consistently held that 'best efforts' and 'commercially reasonable efforts' are not identical standards, though the practical gap between them is narrower than many practitioners assume. 'Best efforts' historically implied an obligation to pursue every available avenue regardless of cost. 'Commercially reasonable efforts' permits the obligated party to weigh the burden and expense of an action against its likely benefit, calibrated against what a reasonable company in that industry would do in comparable circumstances. In CVR agreements, 'commercially reasonable efforts' is the dominant standard because it acknowledges that acquirers must integrate the acquired pipeline into a broader portfolio. The Williams Companies line of Delaware cases confirms that this standard still imposes real obligations and that courts will scrutinize whether the acquirer actually pursued milestone achievement in good faith.
How are CVR payments taxed for selling shareholders?
The tax treatment depends on whether the CVR is treated as an open transaction or closed transaction at signing. Under the open transaction doctrine recognized in Burnet v. Logan, if the CVR's fair market value cannot be reasonably ascertained at closing, the seller may defer gain recognition until payments are actually received, recovering basis first. However, the IRS has narrowed open transaction treatment significantly, and most CVRs today are treated as having an ascertainable fair market value that must be included in the amount realized at closing. If installment sale treatment is available, sellers may spread gain recognition over the period during which CVR payments are received. The interaction between installment method rules under Section 453 and contingent payment obligations is technically complex and requires careful analysis before the transaction closes.
When does Section 1001 require immediate gain recognition on a CVR?
Section 1001 of the Internal Revenue Code requires sellers to recognize gain or loss in the year of the sale in an amount equal to the amount realized minus the adjusted basis in the transferred property. For CVR purposes, the 'amount realized' includes the fair market value of any contingent payment right received. If the CVR has an ascertainable fair market value at closing, the full value is included in the amount realized and tax is owed in the year of closing even if the seller receives no cash payment. The practical consequence is that sellers may owe tax now on value they may never actually receive if milestones are not achieved. Structuring the CVR to qualify as a contingent payment installment obligation under Treasury Regulation 15a.453-1 can defer this recognition, but the contingency must meet specific technical requirements.
What fiduciary duties does a CVR trustee owe to rights holders?
A CVR trustee typically owes contractual rather than fiduciary duties, with the scope defined entirely by the CVR agreement. Unlike an indenture trustee, a CVR trustee is not subject to the Trust Indenture Act unless the CVRs are registered debt securities, which they typically are not. The agreement will define the standard of care, which is often limited to gross negligence or willful misconduct. The trustee's core function is to monitor milestone achievement, review acquirer compliance reports, and act on behalf of CVR holders when directed to do so. Because individual CVR holders are often dispersed and hold small dollar amounts, the trustee is the practical enforcement mechanism. Counsel should negotiate the trustee's authority to initiate litigation, the indemnification provisions, and the ability of large institutional CVR holders to direct the trustee's actions.
What are the key differences between tradable and non-tradable CVRs?
Tradable CVRs are registered under the Securities Act and may be listed on an exchange or traded over the counter, giving sellers liquidity and price discovery. Non-tradable CVRs are contractual rights that cannot be assigned except in limited circumstances such as death or estate transfers, and they create no secondary market. The choice has significant legal consequences. Tradable CVRs require SEC registration, ongoing Exchange Act reporting if the issuer is public, and compliance with securities fraud antifraud provisions. They also require appointment of a transfer agent and compliance with DTC procedures. Non-tradable CVRs are simpler to administer but deny sellers any ability to monetize the contingent payment before milestone resolution. Most pharmaceutical CVRs issued in strategic acquisitions are non-tradable to reduce administrative burden, though high-profile transactions sometimes use tradable structures.
Can CVR holders obtain specific performance if the acquirer breaches its efforts obligations?
Specific performance is available as a remedy under Delaware law if the CVR agreement expressly provides for it and the CVR holders can demonstrate that monetary damages are an inadequate remedy. Because CVR milestone outcomes depend on highly individualized commercial and regulatory decisions that are difficult to value precisely, courts have found that irreparable harm sufficient to support specific performance can exist. However, courts are reluctant to order an acquirer to pursue a particular drug development program on a specific timeline, because judicial supervision of complex pharmaceutical operations is impractical. In practice, specific performance orders in CVR disputes have focused on requiring the acquirer to comply with specific procedural obligations, such as providing required disclosures or completing required regulatory submissions, rather than dictating the operational decisions underlying milestone achievement.
What post-merger integration duties does an acquirer owe to CVR holders during the earnout period?
An acquirer owes CVR holders whatever obligations the CVR agreement expressly imposes, plus an implied covenant of good faith and fair dealing that prohibits actions taken in bad faith to frustrate milestone achievement. Post-merger integration decisions such as shifting development resources to competing programs, deprioritizing regulatory submissions, restructuring the sales force, or reducing the marketing budget for a CVR-bearing product all carry legal risk if they can be shown to have impaired milestone achievement. Delaware courts evaluating CRE claims look at whether the acquirer allocated resources consistent with what a reasonable company in the same business would have allocated absent the contingent payment obligation. Acquirers should document business rationale for all integration decisions that affect CVR products, maintain carve-out budgeting for CVR programs, and preserve communications about milestone strategies throughout the earnout period.
Related Resources
This article is part of Acquisition Stars' life sciences and pharmaceutical M&A legal guide. Related analyses in this series address the full range of legal considerations in pharmaceutical transactions:
- Life Sciences and Pharmaceutical M&A: Legal Guide - Overview of transaction structure, diligence, regulatory considerations, and deal mechanics across life sciences acquisitions.
- FDA Approval Transfers in Pharmaceutical M&A: BLA and NDA Assignments - How FDA marketing authorizations transfer in acquisitions, including assignment mechanics, FDA notification requirements, and change of ownership procedures.
- Clinical Trial Diligence and IND/CTA Transfer in M&A Transactions - Investigational new drug application and clinical trial authorization diligence in pharmaceutical acquisitions, including transfer mechanics and regulatory compliance considerations.
Counsel on Pharmaceutical CVR Transactions
Acquisition Stars advises on contingent value right structuring, milestone definition, efforts obligation negotiation, and CVR dispute resolution in pharmaceutical and life sciences M&A transactions. If you are structuring a transaction that involves contingent consideration or evaluating existing CVR rights, submit your transaction details for an engagement assessment.
Related Practice Areas
Our attorneys handle M&A transactions and securities matters nationwide. Alex Lubyansky leads every engagement personally.